Ken Griffin’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.2M Buy
955,100
+447,600
+88% +$6.69M ﹤0.01% 2911
2026
Q2
$7.39M Buy
507,500
+393,900
+347% +$6.98M ﹤0.01% 4059
2026
Q1
$2.15M Sell
113,600
-303,900
-73% -$4.91M ﹤0.01% 5926
2025
Q4
$7.3M Sell
417,500
-308,900
-43% -$5.81M ﹤0.01% 3700
2025
Q3
$15M Buy
726,400
+332,700
+85% +$8.07M ﹤0.01% 2684
2025
Q2
$8.38M Sell
393,700
-900
-0.2% -$20.5K ﹤0.01% 3284
2025
Q1
$7.61M Buy
394,600
+79,300
+25% +$1.59M ﹤0.01% 3238
2024
Q4
$5.63M Sell
315,300
-142,500
-31% -$2.76M ﹤0.01% 3768
2024
Q3
$10M Buy
457,800
+392,300
+599% +$5.49M ﹤0.01% 2888
2024
Q2
$511K Buy
65,500
+61,800
+1,670% +$334K ﹤0.01% 7995
2024
Q1
$15.3K Buy
3,700
+3,600
+3,600% +$14.3K ﹤0.01% 13196
2023
Q4
$261 Buy
+100
New +$206 ﹤0.01% 14070
2023
Q2
– Sell
-8,500
Closed -$14.9K – 15150
2023
Q1
$14.9K Sell
8,500
-118,500
-93% -$323K ﹤0.01% 13276
2022
Q4
$540K Buy
+127,000
New +$231K ﹤0.01% 8078
2022
Q1
– Sell
-15,700
Closed -$42K – 14498
2021
Q4
$42K Sell
15,700
-8,300
-35% -$39.9K ﹤0.01% 13343
2021
Q3
$120K Sell
24,000
-6,700
-22% -$48.1K ﹤0.01% 12647
2021
Q2
$229K Buy
+30,700
New +$201K ﹤0.01% 11870

Other funds holding SMMT

Ken Griffin's SMMT Position: Q3 2026 in Review

Ken Griffin increased its Summit Therapeutics (SMMT) stake by 119% in Q3 2026, buying an estimated $30.8M and bringing the position to 3,783,589 shares worth $64M. The position accounts for 0.01% of the portfolio, ranked #1333.

Ken Griffin first reported a position in SMMT in Q4 2018 and has held it in 19 quarters since. 298 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Ken Griffin held 3,783,589 shares of Summit Therapeutics worth $64M as of Q3 2026.
  • Ken Griffin bought 2,057,873 Summit Therapeutics shares in Q3 2026, an estimated $30.8M.
  • Summit Therapeutics made up 0.01% of Ken Griffin's portfolio in Q3 2026, its #1333 holding.
  • Ken Griffin first reported a position in Summit Therapeutics in Q4 2018 and has held it in 19 quarters since.
  • 298 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.